CancerFax - Conquering cancer

For nearly eight years, Savina and her family have lived through the ups and downs of leukemia.

Countless hospital visits, treatments, relapses, and challenging decisions shaped her childhood with both uncertainty and remarkable courage.

When treatment options at home became limited, her family chose to keep moving forward. They came to GoBroad, where Savina underwent CAR-T therapy followed by a hematopoietic stem cell transplant, with close monitoring and coordinated care at every stage.

The journey was difficult, but months later, Savina returned stronger, healthier, and full of new energy.

A beautiful milestone in a long journey of strength, resilience, and hope.

Looking for advanced treatment options for blood cancers or other complex cancer cases? CancerFax helps patients explore trusted global treatment pathways.

WhatsApp: wa.me/12137895655

#CancerFax #Leukemia #CARTCellTherapy #StemCellTransplant #ChildhoodCancer #CancerJourney #Hope #Oncology #CancerSupport #AdvancedTreatment #PatientCare #MedicalTravel #GlobalCancerCare

2 weeks ago | [YT] | 1

CancerFax - Conquering cancer

We’ve been talking about why NGS matters. Now I want to hear from you.

What is your BIGGEST barrier to ordering NGS testing for your patients?

💰 Cost—it's too expensive for most patients
⏰ Turnaround time — results take too long to be clinically useful
📍 Availability — no reliable NGS lab accessible to me
📊 Interpretation — I’m not sure how to act on NGS results



Please enter your response in the comment box.



Every barrier has a solution. But we need to understand which barriers matter most to Indian oncologists RIGHT NOW.



Vote, and tell us more in the comments. Your input is directly shaping how we approach this problem at CancerFax.



#DecodeTheCancer #CancerFax #NGSTesting #PrecisionOncology #OncologyEducation #CancerCareIndia

1 month ago | [YT] | 2

CancerFax - Conquering cancer

Every cancer has a genetic story behind it. NGS, or next-generation sequencing, helps us read that story and choose therapies that truly match the biology of the disease, allowing for personalized treatment plans that can significantly improve patient outcomes.

At CancerFax, we strongly believe genomic testing should become a routine part of cancer care so patients can access the most precise and effective treatment options available today.

From DNA to Drug Selection: How NGS Actually Works?

Your patient has advanced cancer. You suspect there might be a targeted mutation. Here’s what happens when you order NGS (next-generation sequencing):

Step 1: Sample Collection
Tumor tissue (biopsy or surgical specimen) or a liquid biopsy (blood draw) is collected.

Step 2: DNA Extraction
Genomic DNA is extracted from tumor cells and fragmented into millions of small pieces.

Step 3: Library Preparation
DNA fragments are tagged and prepared for sequencing. Target genes are captured using a panel (e.g., 300–500 cancer-related genes).

Step 4: Sequencing
Millions of DNA fragments are read simultaneously; this is the “next-generation” part. Unlike Sanger sequencing (1 gene at a time), NGS reads thousands of genes in parallel.

Step 5: Bioinformatics Analysis
Sophisticated algorithms compare the tumor DNA to a reference genome, identifying mutations, fusions, copy number changes, TMB, and MSI status.

Step 6: Clinical Report
Results are compiled into an actionable report: which mutations were found, which therapies they respond to, and which clinical trials are available.

The entire process takes 7–14 days from sample to report.

One test. Hundreds of answers. That’s the power of NGS.

Save this post. Share it with a colleague who’s curious about genomic testing.

#DecodeTheCancer #CancerFax #NGSTesting #GenomicTesting #MolecularOncology #CancerGenomics #TargetedTherapy

2 months ago | [YT] | 1

CancerFax - Conquering cancer

Quick question for my oncology colleagues in India:


How often do you currently order comprehensive genomic testing (NGS) for your advanced cancer patients?


🟢 Always: It’s part of my standard workup.
🟡 Sometimes: For specific cancer types or when standard therapy fails.
🟠 Rarely: Cost and access are barriers.
🔴 Never: I’m not sure when it’s indicated.


No judgment here. This is about understanding our community's status so we can plan our next steps.



Drop your thoughts in the comments. What's the biggest barrier you face?

Results from this poll will shape the content we share in the coming weeks.


#DecodeTheCancer #CancerFax #PrecisionOncology #OncologyEducation #GenomicTesting

2 months ago | [YT] | 0

CancerFax - Conquering cancer

Single-gene testing vs. NGS panel testing here’s what every oncologist should know.

The old approach: test one gene at a time.
• EGFR first. Wait 5–7 days.
• Negative? Try ALK. Wait again.
• Still negative? Test ROS1. More waiting.
• Weeks lost. Tissue depleted. Options narrowing.

The NGS approach: test 300+ genes simultaneously.
• One sample. One test. One comprehensive report.
• Actionable mutations, fusions, amplifications, TMB, MSI — all at once.
• The report provides results that directly correspond to approved therapies and clinical trials.

Single-gene testing misses up to 50% of actionable alterations that NGS would catch.

In 2026, can we afford to test one gene at a time?

Swipe through the carousel to see the full comparison. Save it for your next tumour board.

#DecodeTheCancer #CancerFax #NGSTesting #GenomicTesting #CancerGenomics #OncologyEducation

2 months ago | [YT] | 0

CancerFax - Conquering cancer

Today, on World Cancer Day, we stand united in the fight against cancer. 💙
At CancerFax, we're committed to connecting patients with cutting-edge immunotherapy and cellular therapy treatments that offer new hope and possibilities.

Every day, we work to bridge the gap between innovative cancer care and those who need it most.

This World Cancer Day, let's remember: early detection saves lives, research brings hope, and together, we are stronger than cancer.

To everyone affected by cancer—patients, survivors, caregivers, and medical professionals—we see you, we support you, and we're here for you.

Let's continue to push boundaries, share knowledge, and fight for a world where cancer is no longer a life sentence.

Together, we can close the care gap. 🌍

#WorldCancerDay #CloseTheCareGap #CancerFax #CancerAwareness #ImmunotherapyTreatment #CellularTherapy #CancerResearch #HopeForCancer #CancerCare #CancerSupport #CancerCommunity #InnovativeTreatment #CancerFighters #CancerSurvivors #EndCancer #GlobalHealth #HealthcareInnovation #OncologyExperts #CancerTreatment #TogetherWeCan

2 months ago | [YT] | 0

CancerFax - Conquering cancer

✨ Hope on the horizon for liver cancer patients: GPC3 CAR-T therapy ✨

Liver cancer (especially advanced hepatocellular carcinoma, HCC) is hard to treat but recent advances in immunotherapy are offering real reason for optimism. One of the most promising strategies: CAR-T cells engineered to target Glypican‑3 (GPC3), a protein often found on HCC cells but rarely on healthy cells.

What makes GPC3 CAR-T therapy special?

GPC3 is overexpressed in many HCC tumors, making it a useful “flag” for the immune system to recognize cancer cells while sparing healthy tissue.

Preclinical and early clinical studies have indicated that CAR-T cells targeting GPC3 can kill liver cancer cells effectively. Early lab trials showed strong anti-tumor activity.

What the data says so far?

In a first-in-human study involving 13 advanced HCC patients, infusion of GPC3-CAR-T cells (median dose ~ 19.9 ×10⁸ cells) showed early signs of anti-tumor activity. Two patients had partial responses; one had stable disease lasting over 44 months.

For that same cohort, overall survival at 6 months was ~50.3%. At 1 year, ~42.0%. At 3 years, ~10.5%.

A newer “armored” version, C-CAR031 a next-generation GPC3 CAR-T showed strong results in early trials: in a 2024 report, among evaluable patients (with advanced HCC), ~90.9% showed tumor reduction; disease control rate was 90.9%, and objective response rate was 50.0% (rising to 57.1% at the highest dose level).

Why is this significant?

Treating solid tumors like HCC with CAR-T has always been harder than blood cancers. But targeting GPC3 offers a more selective, less toxic approach. As newer versions with “armored” CAR-T cells or dual-targeting strategies evolve, we may see even stronger, more durable responses.

If you or someone you know wants to learn more about ongoing trials or GPC3-CAR-T therapy, feel free to reach out.

📞 Contact: CancerFax
WeChat / WhatsApp: +86 182 1759 2149

#LiverCancer #HCC #CAR_T #Immunotherapy #GPC3 #CancerResearch #CancerHope

4 months ago | [YT] | 0

CancerFax - Conquering cancer

Personalized, AI-Driven TCRT-T Cell Therapy: Now in Clinical Trials at CAMS, National Cancer Center, Beijing

A new generation of cancer treatment is taking shape in China. Researchers at CAMS, National Cancer Center, are running clinical trials on personalized, AI-driven, multi-targeted TCRT-T cell therapy.

This approach combines deep-learning prediction models with advanced T-cell engineering to identify the most effective TCR targets for each patient. Instead of relying on a single marker, the therapy can address multiple tumor antigens at once, improving the chances of a durable response and reducing relapse.

These trials may offer new hope for patients who have exhausted conventional options, especially in solid tumors where CAR-T has had limitations.

If you want to check eligibility, understand costs, or explore travel and treatment support in China, we’re here to guide you every step of the way.

📩 WeChat / WhatsApp: ‪+86 182 1759 2149‬

CancerFax | Advanced Cancer Treatment Support Worldwide

#TCRTTCellTherapy #AIDrivenTherapy #PersonalizedCancerTreatment #CAMSChina #NationalCancerCenter #AdvancedImmunotherapy #SolidTumorTreatment #CancerClinicalTrials #NextGenOncology #CancerFax

4 months ago | [YT] | 0

CancerFax - Conquering cancer

CAR-T Cell Therapy Targeting NKG2DL-Positive Solid Tumors

Researchers at the Chinese Academy of Medical Sciences and the National Cancer Center are developing a new type of CAR-T cell therapy that specifically targets solid tumors with NKG2DL, which are often found in aggressive cancers.

This approach targets stress-induced ligands, which are commonly expressed on many aggressive cancers, thereby enabling a broader and more precise anti-tumor response.

These ongoing clinical trials aim to overcome long-standing barriers in solid tumor treatment, including resistance, immune evasion, and limited therapeutic options. If successful, NKG2DL-CAR-T could offer a promising path for patients who have exhausted conventional therapies.

If you or your loved one is exploring advanced treatment options, we can help with eligibility checks and enrollment guidance.

📩 WeChat / WhatsApp: ‪+86 182 1759 2149‬

CancerFax | Advanced Cancer Treatment Management

#CARTCellTherapy #NKG2DL #SolidTumorTreatment #CancerResearchChina #Immunotherapy #AdvancedCancerCare #ClinicalTrialsChina #CancerInnovation #OncologyUpdates

4 months ago | [YT] | 0

CancerFax - Conquering cancer

💔 The Silence is Costing Lives: Why Women Delay Diagnosis 💔

Swipe through this critical carousel to understand the hidden barriers that prevent women from seeking early medical care, and how we can work together to change the narrative.

Here's what you'll see:

The Reality: It’s driven by Fear, Stigma, and Misinformation. Too many women wait when symptoms appear, putting their health at serious risk.

The Impact: Late diagnosis leads to advanced tumor growth, limited treatment options, and immense emotional hardship.

The Barriers: From the high cost of treatment to the fear of social judgment, we break down the obstacles.

How We Can Help: We need collective action to educate, encourage open conversations, and make screening accessible.

It's time to make early diagnosis the norm. Every conversation matters. Every voice counts.

ACTION STEPS:
Swipe and Share: Help us break the stigma by sharing this post.

Speak Up: Drop a comment below with your ideas on improving healthcare access!

#BreastCancerAwareness #HealthEquity #WomensHealth #EarlyDiagnosis #BreakingTheStigma #CommunityPost

Skip the Carousel

1 2 3 4 5 6

6 months ago (edited) | [YT] | 1